A Multi-Center, Inpatient and Ambulatory, Phase 2, Doubleblind, Randomised, Placebo-Controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia.

Trial Profile

A Multi-Center, Inpatient and Ambulatory, Phase 2, Doubleblind, Randomised, Placebo-Controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2012

At a glance

  • Drugs MIN 101 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Cyrenaic Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2010 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2010 Results have been reported in a Cyrenaic Pharmaceuticals media release.
    • 23 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top